Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.
Steinhardt MJ, Truger M, Bittrich M, Zhou X, Noderer J, Riedhammer C, Xiao X, Gawlas S, Weis P, Eisele F, Haferlach C, Mersi J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM. Steinhardt MJ, et al. Among authors: einsele h. Haematologica. 2024 Mar 1;109(3):979-981. doi: 10.3324/haematol.2023.283472. Haematologica. 2024. PMID: 37794827 Free PMC article. No abstract available.
All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
García-Guerrero E, Rodríguez-Lobato LG, Sierro-Martínez B, Danhof S, Bates S, Frenz S, Haertle L, Götz R, Sauer M, Rasche L, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Prommersberger SR. García-Guerrero E, et al. Among authors: einsele h. Haematologica. 2023 Feb 1;108(2):568-580. doi: 10.3324/haematol.2022.281339. Haematologica. 2023. PMID: 36722406 Free PMC article.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt MJ, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez MM, Munawar U, Riedel A, Han S, Maurits E, Overkleeft HS, Florea B, Einsele H, Kortüm KM, Driessen C, Besse L, Rasche L. Zhou X, et al. Among authors: einsele h. Haematologica. 2023 Jun 1;108(6):1628-1639. doi: 10.3324/haematol.2022.282225. Haematologica. 2023. PMID: 36727403 Free PMC article.
Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment.
Cebulla N, Schirmer D, Runau E, Flamm L, Gommersbach S, Stengel H, Zhou X, Einsele H, Reinhold AK, Rogalla von Bieberstein B, Zeller D, Rittner H, Kortüm KM, Sommer C. Cebulla N, et al. Among authors: einsele h. J Neurol. 2023 Jun;270(6):2997-3007. doi: 10.1007/s00415-023-11624-2. Epub 2023 Feb 18. J Neurol. 2023. PMID: 36802032 Free PMC article. Clinical Trial.
A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials.
Fleischer A, Zapf L, Allgaier J, Jordan K, Gelbrich G, Pryss R, Schobel J, Bittrich M, Einsele H, Kortüm M, Maatouk I, Weinhold N, Rasche L. Fleischer A, et al. Among authors: einsele h. J Cancer Res Clin Oncol. 2023 Nov;149(14):12897-12902. doi: 10.1007/s00432-023-05137-8. Epub 2023 Jul 19. J Cancer Res Clin Oncol. 2023. PMID: 37466796 Free PMC article. No abstract available.
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ. Lee H, et al. Among authors: einsele h. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31. Nat Med. 2023. PMID: 37653344 Free PMC article.
Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.
Bittrich M, Hetterich R, Solimando AG, Krebs M, Loda S, Danhof S, Anton S, Zhou X, Kerscher A, Beilhack A, Kortüm KM, Rasche L, Einsele H, Knop S, Hartmann S. Bittrich M, et al. Among authors: einsele h. Clin Exp Med. 2023 Dec;23(8):5215-5226. doi: 10.1007/s10238-023-01100-6. Epub 2023 Oct 7. Clin Exp Med. 2023. PMID: 37805620 Free PMC article.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P. Mateos MV, et al. Among authors: einsele h. Haematologica. 2023 Aug 1;108(8):2192-2204. doi: 10.3324/haematol.2022.280482. Haematologica. 2023. PMID: 36546453 Free PMC article.
Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany.
Morbach C, Papagianni A, Ihne-Schubert S, Cejka V, Steinhardt M, Fette G, Held M, Geier A, Einsele H, Frantz S, Knop S, Sommer C, Störk S. Morbach C, et al. Among authors: einsele h. Clin Res Cardiol. 2024 May;113(5):653-655. doi: 10.1007/s00392-023-02163-x. Epub 2023 Feb 23. Clin Res Cardiol. 2024. PMID: 36820871 Free PMC article. No abstract available.
973 results